

Best Global Medical Cannabinoid Development Company 2023

Canadian company CanaQuest is a clinical-stage life sciences enterprise. Its focus is directed towards drug discovery and development of the next-generation of targeted therapeutics within the endocannabinoid system and specific brain receptors. Its branded medical cannabis product is known as Mentanine®, and is widely available for sale in the United States.

CanaQuest has a strong company focal point to bring innovative products to the market, specifically targeted at treating neurological conditions such as epilepsy, anxiety, depression, addiction, and post-traumatic stress disorder. It began life as an algae company, something that is much in demand within the health and beauty industry for its many therapeutic qualities. To this end, it worked professionally alongside a professor at the University of Waterloo, resulting in the construction of an algae bioreactor. This in-depth research led to CanaQuest gaining an understanding about essential fatty acids, often known as omega-3s, which the human body is incapable of producing alone. Despite this, omega-3s are still a necessary component for good health, typically accessed by dietary means such as eating fish, eggs, and/or taking supplements.

Following on from its innovative work with algae, CanaQuest was asked if it could extract oils from cannabis. It entered the market with a clear aim to examine cannabis from a scientific perspective. It also wanted to help people, as much as it could. The company had its preclinical trials conducted by the number one neuroscientist in Canada, Dr Steven Laviolette. Dr Laviolette is a professor and neuroscientist at Western University, with decades of experience in the fields of mental health and cannabinoids. Remarkably, the trials demonstrated a decrease in



anxiety, depression, PTSD, schizophrenia, opioid addiction, and inflammation in the brain. Further Clinical Studies for epilepsy were conducted at the Ontario Brain Institute by Dr. W McIntyre Burnham, emeritus professor at the University of Toronto. These studies were designed to compare the company's 'Drug Candidate, CQ-001', to standard CBD. The results demonstrated a 50% increase in reduction of seizures.

“If people are taking cannabis – or any medication for medicinal purposes – and their receptors are defective or not working at all - the benefits will either be nominal or there will be no indications at all. We wanted to help innovate that space.”

Going back to the algae bioreactor timeframe of the company for a moment, it is important to note that at that time CanaQuest discovered most people have significant deficiencies in essential fatty acids, specifically the omegas known as DHA and EPA. Owing to this, most people's receptors to omega 3 are not working effectively, if at all. When the company conducted its presentation to Dr. Laviolette, prior to him coming on board, it wanted to focus on the combination of DHA and EPA with cannabinoid molecules. This interesting research perspective from the company precipitated Dr Laviolette joining as a scientific partner. His embrace of the scientific approach rubber stamped the company's intentions to explore the concepts further.

Soon it became clear that CanaQuest's new partner, Dr Laviolette, and his team had made a breakthrough discovery. This consisted of a new pathway into the brain to address mental health neurological conditions and mental ailments. In the pre-clinical trials, CBD, DHA, and EPA molecules bonded and began to work synergistically. They also attached to the PPAR receptors, facilitating a pathway to cross the blood-brain barrier (BBB) to access a section of the brain responsible for regulating emotions, such as anxiety, depression, and PTSD, with an effect and efficacy that was amplified.

The innovation that allowed this to happen was, of course, the formulation consisting of cannabidiol, or CBD, element combined with essential fatty acids, working synergistically. It is in effect proving the winning validity of a CBD/omega 3 combination. CBD did not manage to achieve this result by itself, in the pre-clinical trial research.

In the Clinical Study, conducted at the Ontario Brain Institute, it was only CQ-001 that demonstrated the statistically significant Clinical Dose and efficacy Study results described above. These results set the stage for substantially smaller dosages of CBD being capable of generating desired results, provided it is combined with essential fatty acids. Another particularly gratifying result is that the drug candidate operates without the negative side effects, and will define a dosage of CQ-001 for a clinical trial. The Phase III, double-blind trial, is now proposed with participation of 60 patients.

Furthermore, the regulatory pathways are mapped out and the stage is set to submit applications to Health Canada to go through the process of obtaining approval for a drug as being eligible for Priority Review Status, with a projected approval of timeframe of approximately 18 to 24 months, and the US-FDA to go through the process of obtaining drug eligible for Orphan Drug Status & Priority Review Voucher (PRV), with a projected approval timeframe of approximately 3 years.

“The team also found a notable reduction in inflammation in the brain, which could be highly beneficial for other neurological conditions. So, not only did this help innovate the cannabis industry, but the findings can be useful for the universal world of science.”

CanaQuest is standing on the brink of a major medical achievement, and not just in the world of medical cannabinoids. It describes it as a transformative, data collection, and growth stage, with a company focus on addressing not just mental health, but potentially other neurological conditions as well. CanaQuest's future will entail getting sufficient financing in place to conduct the intended clinical studies in 2023 and 2024. It needs these to evaluate the efficacy of Mentanine® on targeted populations, particularly those struggling with transitional issues. It also hopes to conduct a Phase III clinical trial regarding the effects on rare neurological conditions that fall under the umbrella banner of Epilepsy, in 2024.

The company is delighted to share that it has recently signed a Master Service Agreement with Neeka Health, which hopefully will allow it to progress its studies into the efficacy of Mentanine®. Neeka conducted extensive due diligence on over 90 companies



in the cannabinoid research space, before choosing to accept CanaQuest alone. Dr. Hunter Land, the CSO of Neeka, co-led the clinical development of Epidiolex® (FDA-approved prescription CBD) for GW Pharma. He will be leading all the studies for Neeka and CanaQuest.

Future goals for CanaQuest involve continuing to build its team and helping to educate people in need. Ultimately, the company is set on improving the quality of life for as many individuals as it can. It has one further note of great importance to impart, which is to explain to potential customers that individual responses to medications can vary, and of course this includes the effects of Mentanine®. The impact may differ from person to person based on factors such as their unique physiology, metabolism, and overall health. It wants to make it clear that as with any formulated product, it's most important to consult with a medical professional before starting any new medication or supplement. They can provide personalized guidance and dosage recommendations based on your own specific needs and circumstances.

The professional way that CanaQuest conducts itself, and the groundbreaking results it is achieving, with its incredible research, are very much respected. It is no wonder it has been awarded the title Best Global Medical Cannabinoid Development Company 2023, in the Healthcare and Pharmaceutical Awards. Unreserved congratulations go out to it, who we are sure will only continue onwards and upwards with its outstanding medical developments.

Company: CanaQuest Medical Corp
Web Address: www.canaquest.com & www.canaqueststore.com
Contact Name: Paul Ramsay CEO
paul@canaquest.com



CanaQuest

GHP Healthcare & Pharma Awards 2023